tiprankstipranks
Luye Pharma Group Ltd. (HK:2186)
:2186
Hong Kong Market
Holding HK:2186?
Track your performance easily

Luye Pharma Group (2186) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

2186 Financial Forecast

2186 Earnings Forecast

Next quarter’s earnings estimate for 2186 is HK$0.12 with a range of HK$0.12 to HK$0.12. The previous quarter’s EPS was HK$0.11. 2186 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.51% of the time in the same period. In the last calendar year 2186 has Outperformed its overall industry.
Next quarter’s earnings estimate for 2186 is HK$0.12 with a range of HK$0.12 to HK$0.12. The previous quarter’s EPS was HK$0.11. 2186 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.51% of the time in the same period. In the last calendar year 2186 has Outperformed its overall industry.

2186 Sales Forecast

Next quarter’s sales forecast for 2186 is HK$3.65B with a range of HK$3.65B to HK$3.65B. The previous quarter’s sales results were HK$3.33B. 2186 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 53.85% of the time in the same period. In the last calendar year 2186 has Outperformed its overall industry.
Next quarter’s sales forecast for 2186 is HK$3.65B with a range of HK$3.65B to HK$3.65B. The previous quarter’s sales results were HK$3.33B. 2186 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 53.85% of the time in the same period. In the last calendar year 2186 has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on HK:2186
Eva Zhao
Not Ranked
Citi
HK$2.4HK$4
Buy
96.08%
Upside
Upgraded
08/30/24
Citi Upgrades Luye Pharma Group Ltd. (2186:HK) (LYPHF) to BuyCiti analyst Eva Zhao upgraded Luye Pharma Group Ltd. (2186:HK) (OTC: LYPHF) from Sell to Buy with a price target of HK$4.00 (from HK$2.40).
Morgan Stanley
HK$2.7
Sell
32.35%
Upside
Reiterated
03/31/24
Morgan Stanley Reiterates Underweight Rating on Luye Pharma Group Ltd. (2186:HK) (LYPHF)Morgan Stanley analyst Sean Wu reiterated an Underweight rating and HK$2.70 price target on Luye Pharma Group Ltd. (2186:HK) (OTC: LYPHF).

Best Analysts Covering Luye Pharma Group

Which Analyst Should I Follow If I Want to Buy HK:2186 and Sell After:
1 Month
xxx
Success Rate
1/3 ratings generated profit
33%
Average Return
+9.40%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of +9.40% per trade.
3 Months
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+24.80%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +24.80% per trade.
1 Year
Sean Wu CFAMorgan Stanley
Success Rate
3/3 ratings generated profit
100%
Average Return
+48.60%
reiterated a sell rating 10 months ago
Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.60% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+37.93%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2186 Analyst Recommendation Trends

Rating
Aug 21
Sep 21
Jan 22
Jan 24
Aug 24
Strong Buy
0
0
0
0
1
Buy
0
0
0
0
0
Hold
1
1
1
1
0
Sell
3
3
3
2
2
Strong Sell
0
0
0
0
0
total
4
4
4
3
3
In the current month, 2186 has received 1 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. 2186 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

2186 Stock Forecast FAQ

What is HK:2186’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2186’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2186, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Luye Pharma Group Ltd. a Buy, Sell or Hold?
      Currently, no data Available
      What is Luye Pharma Group Ltd.’s share price target?
      Currently, no data Available
      What do analysts say about Luye Pharma Group Ltd.?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Luye Pharma Group Ltd.?
      To buy shares of HK:2186, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis